Paris,  June   22,  2017  –  GenSight  Biologics  (Euronext:  SIGHT,  ISIN:  FR0013183985,   PEA-PME eligible),  (“GenSight  Biologics”  or  the  “Company”),  a  biotechnology   company   discovering   and developing  novel  gene  therapies  for neurodegenerative  retinal  diseases  and diseases  of the central nervous system, today announced the launch of a capital increase of around €20 million.

The funds raised will be allocated to prepare the launch of GS010 in Europe and the United States, and especially the financing related to the marketing and market access, as well as the establishment  of a marketing infrastructure.

Gross proceeds from the transaction are expected to be approximately €20 million. The purpose of this capital increase is to finance preparations for the marketing of GS010 and improve the financial visibility for the Company through to the 1st quarter of 2019.

This fund raising will correspond to a maximum of 3,908,090 new shares, with a par value of €0.025 per share,  representing  approximately  20%  of the outstanding  share  capital  of the Company  on a non- diluted basis. The subscription price per share will be determined in accordance with the 22nd resolution of the combined general assembly of May 31, 2017.

The subscription price per share will be set in accordance with the 22nd  resolution of the extraordinary general meeting of the shareholders of the Company held on May 31, 2017. The subscription price per share  will  be  set  at  a  maximum  discount  of  15%  to  the  volume  weighted  average  price  of  the Company’s  shares over the last 3 trading days before pricing, namely June 20 to June 22, 2017, in accordance  with  the  22nd   resolution  of  the  combined  general  meeting  of  the  shareholders  of  the Company held on May 31, 2017.

The capital  increase  is open  only to the categories  of investor  (including  legal)  defined  in the 22nd resolution abovementioned (i.e habitually investing in the pharmaceutical, biotechnological, ophthalmological, neurodegenerative diseases or medical technologies sectors).

The issue of new shares will be subject to a book-building process for qualified investors in accordance with Article  3.2(a) of the European  Directive  2003/71/EC  of the European  Parliament  and European Council  dated  November  4,  2003  (as  amended)  and  meeting  the  predetermined  criteria  within  the European Economic Area, and in certain other countries.

The Company will announce the results of the capital increase as soon as possible after closing of the book-building  in a subsequent  press release. Settlement  and delivery of the new shares and the new shares’ admission to trading is expected to occur on June 27, 2017 on the regulated market of Euronext in Paris.

Simultaneously  with  the  determination  of the  final  terms  and  conditions  of the  capital  increase,  the Company will enter into a lock-up agreement ending 90 calendar days after the date of the pricing of the offering, subject to certain customary exceptions.

Persons acting on behalf of the Company (executives  and/or directors) have also entered into similar lock-up agreements with regard to the Company’s shares that they hold.

A  listing  prospectus,   incorporating   the  2016  registration   document,  registered  with  the  AMF  on April 28, 2017,   under   number   R.17-036,   available   free   of   charge   from   the   Company   website (   and/or   website   of  the  Autorité   des  marchés   financiers   (www.amf-, together with a Securities Note, containing a summary of the prospectus in French and in English, will be submitted to the AMF, with a view to receiving its approval. Attention is drawn to the risk factors related to the Company and its activities presented in chapter 4 of its registration document.

This press release does not constitute a prospectus within the meaning of the Prospectus Directive nor a public offering.

About GenSight Biologics

GenSight Biologics S.A. (GenSight Biologics) is a clinical-stage biotechnology  company discovering and developing novel  therapies  for  neurodegenerative  retinal  diseases  and  diseases  of  the  central  nervous  system.  GenSight Biologics’ pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics   for  retinitis   pigmentosa,   to  help  preserve   or  restore   vision  in  patients   suffering   from  severe degenerative retinal diseases. GenSight Biologics’ lead product candidate, GS010, is in Phase III trials in Leber’s Hereditary  Optic Neuropathy  (LHON),  a rare mitochondrial  disease  that leads to irreversible  low vision and legal blindness  in  teens  and  young  adults.  Using  its  gene  therapy-based   approach,   GenSight  Biologics’  product candidates  are  designed  to be  administered  in a single  treatment  to each  eye  by  intravitreal  injection  to offer patients a sustainable functional visual recovery.


This document  and the information  contained  herein  do not constitute  either an offer to sell or purchase,  or the solicitation of an offer to sell or purchase, securities of GenSight Biologics S.A. (the “Company”).

No communication  and no information in respect of the offering by the Company of its shares may be distributed to the public in any jurisdiction where registration or approval is required. No steps have been taken or will be taken in any jurisdiction outside France where such steps would be required. The offering or subscription  of shares may be subject to specific legal or regulatory restrictions in certain jurisdictions.

This announcement  does not, and shall not, in any circumstances,  constitute  a public offering nor an invitation to the  public  in  connection  with  any  offer.  The  distribution  of  this  document  may  be  restricted  by  law  in  certain jurisdictions.  Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

This announcement  is an advertisement  and not a prospectus  within the meaning of the Prospectus  Directive (as defined below), as implemented in each member State of the European Economic Area.

With respect to the Member States of the European Economic Area (including France) (“Member States”), no action has  been  undertaken  or will  be  undertaken  to make  an  offer  to the  public  of the  securities  referred  to herein requiring  a publication  of a prospectus  in any Member State. As a result, the securities  of the Company  may not and will not be offered in any Member State except in accordance  with the exemptions  set forth in Article 3 of the Prospectus Directive.

For  the  purposes  of  the  provision  above,  the  expression  “offer  to  the  public”  in  relation  to  any  shares  of  the Company in any Member State means the communication  in any form and by any means of sufficient information on the terms of the offer and any securities  to be offered so as to enable an investor to decide to purchase  any securities,  as  the  same  may  be  varied  in  that  Member  State.  The  expression  “Prospectus  Directive”  means Directive  2003/71/EC  (as amended,  including  by Directive  2010/73/EU),  and includes  any relevant  implementing measure in the Member State.

This  document  does  not  constitute  an  offer  of  securities  for  sale  nor  the  solicitation  of  an  offer  to  purchase securities  in the United States or any other jurisdiction  where such offer may be restricted.  Securities  may not be offered  or sold in the United  States  absent  registration  under the U.S. Securities  Act of 1933, as amended  (the “Securities  Act”)  except  pursuant  to  an  exemption  from,  or  in  a  transaction   not  subject  to,  the  registration requirements  thereof. The securities of the Company have not been and will not be registered under the Securities Act, and the Company does not intend to make a public offer of its securities in the United States.

The distribution  of this document  (which  term shall include  any form of communication)  is restricted  pursuant  to Article 21 (restrictions on financial promotion) of Financial Services and Markets Act 2000 (“FMSA”). This document is directed only at persons who (i) have professional  experience  in matters relating to investments  and fall within Article 19(5) (“investment  professionals”)  of the Financial  Services  and Markets  Act 2000 (Financial  Promotions) Order 2005, or (ii) are persons falling within Article 49(2)(a) to (d) (“high net worth companies, unincorporated associations  etc.”) of the Financial  Services  and Markets  Act 2000 (Financial  Promotion)  Order  2005 or (iii) are persons to whom this communication  may otherwise lawfully be communicated  (all such persons in (i), (ii) and (iii) above together being referred to as “Relevant  Persons”).  This document  must not be acted on or relied on in the United  Kingdom  by persons  who are not Relevant  Persons.  Any investment  or investment  activity  to which  this document  relates is available  only in the United Kingdom  to Relevant  Persons,  and will be engaged  in only with such persons.  Any person  other than a Relevant  Person  may not act or rely on this document  or any provision thereof. Persons distributing this document must satisfy themselves that it is lawful to do so.

This document may not be distributed, directly or indirectly, in Canada, Australia or Japan.